Progress in the development of virus-like particle vaccines against respiratory viruses

References

• Pavia AT. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis. 2011;52(Suppl4):S284–9.
   PubMedGoogle Scholar
• Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015;373(5):415–427.
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010;23(1):74–98.
   PubMed Web of Science ®Google Scholar
• Nakano K, Shiroma A, Shimoji M, et al. Advantages of genome sequencing by long-read sequencer using SMRT technology in medical area. Hum Cell. 2017;30(3):149–161.
   PubMed Web of Science ®Google Scholar
• Quan F, Lee Y, Kim K, et al. Progress in developing virus-like particle influenza vaccines. Expert Rev Vaccines. 2016;15(10):1281–1293.
   PubMed Web of Science ®Google Scholar
• Pham D, Grégoire N, Couet W, et al. Pulmonary delivery of pyrazinamide-loaded large porous particles. Eur J Pharm Biopharm. 2015;94:241–250.
   PubMed Web of Science ®Google Scholar
• Schweitzer JW, Justice NA. Respiratory Syncytial Virus Infection (RSV). StatPearls. Anonymous StatPearls Publishing LLC, St. Petersburg (FL); 2019.
   Google Scholar
• Seale AC, Bianchi-Jassir F, Russell NJ, et al. Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis. 2017;65(Suppl2):S200–19.
   PubMedGoogle Scholar
• Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138–2149.
   PubMed Web of Science ®Google Scholar
• Leung DY, Sampson H, Geha R, et al. Pediatric allergy: principles and practice E-Book. Amsterdam, Netherlands: Elsevier Health Sciences; 2010.
   Google Scholar
• Wu N, Yang W, Beineke A, et al. The differentiated airway epithelium infected by influenza viruses maintains the barrier function despite a dramatic loss of ciliated cells. Sci Rep. 2016;6:39668.
   PubMed Web of Science ®Google Scholar
• Kim JI, Park S, Lee I, et al. Genome-wide analysis of human metapneumovirus evolution. PLoS One. 2016;11(4):e0152962.
   PubMed Web of Science ®Google Scholar
• Lévy C, Aerts L, Hamelin M, et al. Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. Vaccine. 2013;31(25):2778–2785.
   PubMed Web of Science ®Google Scholar
• Cox RG, Erickson JJ, Hastings AK, et al. Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model. J Virol. 2014;88(11):6368–6379.
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Vunnava A, et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol. 2010;84(15):7760–7769.
   PubMed Web of Science ®Google Scholar
• Quan FS, Huang C, Compans RW, et al. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81(7):3514–3524.
   PubMed Web of Science ®Google Scholar
• Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31(1):58–83.
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14(3):167.
   PubMed Web of Science ®Google Scholar
• Akahata W, Yang Z, Andersen H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;16(3):334.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kundig TM, et al. The influence of antigen organization on B cell responsiveness. Science. 1993;262(5138):1448–1451.
   PubMed Web of Science ®Google Scholar
• Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol. 2001;75(13):6154–6165.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007;25(19):3871–3878.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Bu F, et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005;23(50):5751–5759.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Van Hoeven N, et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine. 2007;25(21):4283–4290.
   PubMed Web of Science ®Google Scholar
• Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005;18(1):244–251.
   PubMed Web of Science ®Google Scholar
• Park YC, Song JM. Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration. Clin Exp Vaccine Res. 2017;6(1):61–66.
   PubMed Web of Science ®Google Scholar
• Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 2007;20(3):441–452.
   PubMed Web of Science ®Google Scholar
• Rezaei F, Mirshafiey A, Shahmahmoodi S, et al. Influenza Virus-like Particle Containing Two Different Subtypes of Hemagglutinin Confers Protection in Mice Against Lethal Challenge With A/PR8 (H1N1) and A/HK (H3N2) Viruses. Iran Red Crescent Med J. 2013;15(1):75–82.
   PubMed Web of Science ®Google Scholar
• Lee D, Bae S, Park J, et al. Virus-like particle vaccine protects against H3N2 canine influenza virus in dog. Vaccine. 2013;31(32):3268–3273.
   PubMed Web of Science ®Google Scholar
• Giles BM, Ross TM. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine. 2011;29(16):3043–3054.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008;3(1):e1501.
   PubMed Web of Science ®Google Scholar
• Mahmood K, Bright RA, Mytle N, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine. 2008;26(42):5393–5399.
   PubMed Web of Science ®Google Scholar
• Park J, Lee D, Youn H, et al. Protective efficacy of crude virus‐like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respir Viruses. 2013;7(3):340–348.
   PubMed Web of Science ®Google Scholar
• Choi J, Kim M, Kang H, et al. Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens. Vet Microbiol. 2013;162(2–4):623–630.
   PubMed Web of Science ®Google Scholar
• Wu C, Yeh Y, Yang Y, et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One. 2010;5(3):e9784.
   PubMed Web of Science ®Google Scholar
• Haynes JR, Dokken L, Wiley JA, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine. 2009;27(4):530–541.
   PubMed Web of Science ®Google Scholar
• Ren Z, Ji X, Meng L, et al. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus. Virus Res. 2015;200:9–18.
   PubMed Web of Science ®Google Scholar
• Xue C, Tian G, Chen X, et al. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens. Virus Res. 2015;195:35–42.
   PubMed Web of Science ®Google Scholar
• Pillet S, Racine T, Nfon C, et al. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets. Vaccine. 2015;33(46):6282–6289.
   PubMed Web of Science ®Google Scholar
• Liu YV, Massare MJ, Pearce MB, et al. Recombinant virus-like particles elicit protective immunity against avian influenza A (H7N9) virus infection in ferrets. Vaccine. 2015;33(18):2152–2158.
   PubMed Web of Science ®Google Scholar
• Lee D, Park J, Lee Y, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine. 2011;29(23):4003–4007.
   PubMed Web of Science ®Google Scholar
• Kang H, Chu K, Lee D, et al. Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs. PLoS One. 2019;14(6):e0216871.
   PubMed Web of Science ®Google Scholar
• Redkiewicz P, Sirko A, Kamel KA, et al. Plant expression systems for production of hemagglutinin as a vaccine against influenza virus. Acta Biochim Pol. 2014;61:3.
   Web of Science ®Google Scholar
• Lindsay BJ, Bonar MM, Costas-Cancelas IN, et al. Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy. Vaccine. 2018;36(16):2147–2154.
   PubMed Web of Science ®Google Scholar
• Hodgins B, Pillet S, Landry N, et al. A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities. PLoS One. 2019;14(1):e0210009.
   PubMed Web of Science ®Google Scholar
• Kang S, Song J, Quan F, et al. Influenza vaccines based on virus-like particles. Virus Res. 2009;143(2):140–146.
   PubMed Web of Science ®Google Scholar
• Quan FS, Steinhauer D, Huang C, et al. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008;26(26):3352–3361.
   PubMed Web of Science ®Google Scholar
• Margine I, Krammer F. Animal models for influenza viruses: implications for universal vaccine development. Pathogens. 2014;3(4):845–874.
   PubMedGoogle Scholar
• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods. 2006;40(1):60–65.
   PubMed Web of Science ®Google Scholar
• Schwartzman LM, Cathcart AL, Pujanauski LM, et al. An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus. MBio. 2015;6(4):e01044–15.
   PubMed Web of Science ®Google Scholar
• Wang BZ, Quan FS, Kang SM, et al. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol. 2008;82(23):11813–11823.
   PubMed Web of Science ®Google Scholar
• Quan F, Kim M, Lee B, et al. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology. 2012;430(2):127–135.
   PubMed Web of Science ®Google Scholar
• Ross TM, Mahmood K, Crevar CJ, et al. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One. 2009;4(6):e6032.
   PubMed Web of Science ®Google Scholar
• Quan F, Vunnava A, Compans RW, et al. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One. 2010;5(2):e9161.
   PubMed Web of Science ®Google Scholar
• Pushko P, Kort T, Nathan M, et al. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010;28(30):4771–4776.
   PubMed Web of Science ®Google Scholar
• Wang B, Xu R, Quan F, et al. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One. 2010;5(11):e13972.
   PubMed Web of Science ®Google Scholar
• Szécsi J, Boson B, Johnsson P, et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J. 2006;3(1):70.
   PubMedGoogle Scholar
• Song JM, Van Rooijen N, Bozja J, et al. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A. 2011;108(2):757–761.
   PubMed Web of Science ®Google Scholar
• Song J, Hossain J, Yoo D, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology. 2010;405(1):165–175.
   PubMed Web of Science ®Google Scholar
• Qin J, Zhang Y, Shen X, et al. H7 virus-like particles assembled by hemagglutinin containing H3N2 transmembrane domain and M1 induce broad homologous and heterologous protection in mice. Vaccine. 2018;36(33):5030–5036.
   PubMed Web of Science ®Google Scholar
• Jiang W, Wang S, Chen H, et al. A bivalent heterologous DNA virus-like-particle prime-boost vaccine elicits broad protection against both group 1 and 2 influenza A viruses. J Virol. 2017;91(9):e02052–16.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Hidajat R, Hamilton G, et al. Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein. Virology. 2016;487:163–171.
   PubMed Web of Science ®Google Scholar
• Kim Y, Lee Y, Kim M, et al. Cross-protective efficacy of influenza virus M2e containing virus-like particles is superior to hemagglutinin vaccines and variable depending on the genetic backgrounds of mice. Front Immunol. 2017;8:1730.
   PubMed Web of Science ®Google Scholar
• Kim M, Song J, Eunju O, et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther. 2013;21(2):485–492.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim K, Ko E, et al. New vaccines against influenza virus. Clin Exp Vaccine Res. 2014;3(1):12–28.
   PubMedGoogle Scholar
• Music N, Reber AJ, Kim M, et al. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. Vaccine. 2016;34(4):466–473.
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee Y, Kim M, et al. A novel vaccination strategy mediating the induction of lung-resident memory CD8 T cells confers heterosubtypic immunity against future pandemic influenza virus. J Immunol. 2016;196(6):2637–2645.
   PubMed Web of Science ®Google Scholar
• Song B, Kang H, Lee E, et al. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens. Vaccine. 2016;34(5):678–686.
   PubMed Web of Science ®Google Scholar
• Kim M, Lee Y, Ko E, et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol Ther. 2014;22(7):1364–1374.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim K, Ko E, et al. Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles. Virology. 2019;529:111–121.
   PubMed Web of Science ®Google Scholar
• Andersson AC, Håkansson KO, Jensen BAH, et al. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS One. 2012;7(10):e46395.
   PubMed Web of Science ®Google Scholar
• Eliasson DG, El Bakkouri K, Schön K, et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008;26(9):1243–1252.
   PubMed Web of Science ®Google Scholar
• Wu F, Yuan X, Li J, et al. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine. 2009;27(32):4320–4324.
   PubMed Web of Science ®Google Scholar
• Ernst WA, Kim HJ, Tumpey TM, et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine. 2006;24(24):5158–5168.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366(9492):1165–1174.
   PubMed Web of Science ®Google Scholar
• Wei H, Chang W, Lin S, et al. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine. 2011;29(41):7163–7172.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang YC, Feng H, et al. Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice. Biomed Res Int. 2013;686549:2013.
   Google Scholar
• Kim K, Kwon Y, Lee Y, et al. Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine. Virology. 2018;524:172–181.
   PubMed Web of Science ®Google Scholar
• Silva A, Mount A, Krstevska K, et al. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. J Immunol. 2015;194(5):2199–2207.
   PubMed Web of Science ®Google Scholar
• Chung KY, Coyle EM, Jani D, et al. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine. 2015;33(32):3953–3962.
   PubMed Web of Science ®Google Scholar
• Smith GE, Flyer DC, Raghunandan R, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013;31(40):4305–4313.
   PubMed Web of Science ®Google Scholar
• Ko E, Lee Y, Lee Y, et al. Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice. Vaccine. 2019;37(26):3426–3434.
   PubMed Web of Science ®Google Scholar
• Patel JM, Kim M, Vartabedian VF, et al. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomedicine. 2015;11(5):1097–1107.
   PubMed Web of Science ®Google Scholar
• Mohan T, Berman Z, Luo Y, et al. Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses. Sci Rep. 2017;7:40226.
   PubMed Web of Science ®Google Scholar
• Kazaks A, Lu I, Farinelle S, et al. Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates. BMC Biotechnol. 2017;17(1):79.
   PubMedGoogle Scholar
• Chiang C, Beljanski V, Yin K, et al. Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J Virol. 2015;89(15):8011–8025.
   PubMed Web of Science ®Google Scholar
• Beljanski V, Chiang C, Kirchenbaum GA, et al. Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J Virol. 2015;89(20):10612–10624.
   PubMed Web of Science ®Google Scholar
• Li X, Ju H, Liu J, et al. Influenza virus‐like particles harboring H9N2 HA and NA proteins induce a protective immune response in chicken. Influenza Other Respir Viruses. 2017;11(6):518–524.
   PubMed Web of Science ®Google Scholar
• Quan F, Ko E, Kwon Y, et al. Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol. 2013;26(6):385–395.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Yang Y, Graham BS, et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85(15):7788–7796.
   PubMed Web of Science ®Google Scholar
• Lee H, Lee J, Park M, et al. Monoclonal antibody against G glycoprotein increases respiratory syncytial virus clearance in vivo and prevents vaccine-enhanced diseases. PLoS One. 2017;12(1):e0169139.
   PubMed Web of Science ®Google Scholar
• Olson MR, Varga SM. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines. 2008;7(8):1239–1255.
   PubMed Web of Science ®Google Scholar
• Schepens B, Schotsaert M, Saelens X. Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen. Immunotherapy. 2015;7(3):203–206.
   PubMed Web of Science ®Google Scholar
• McGinnes LW, Gravel KA, Finberg RW, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol. 2011;85(1):366–377.
   PubMed Web of Science ®Google Scholar
• Murawski MR, McGinnes LW, Finberg RW, et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2010;84(2):1110–1123.
   PubMed Web of Science ®Google Scholar
• Chaiwatpongsakorn S, Epand RF, Collins PL, et al. Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer. J Virol. 2011;85(8):3968–3977.
   PubMed Web of Science ®Google Scholar
• McGinnes Cullen L, Schmidt MR, Morrison TG. Effect of previous respiratory syncytial virus infection on murine immune responses to F and G protein-containing virus-like particles. J Virol. 2019;93(9):e00087–19.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–1117.
   PubMed Web of Science ®Google Scholar
• McGinnes Cullen L, Schmidt MR, Kenward SA, et al. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein. J Virol. 2015;89(13):6835–6847.
   PubMed Web of Science ®Google Scholar
• Cullen LM, Schmidt MR, Torres GM, et al. Comparison of immune responses to different versions of VLP associated stabilized RSV pre-fusion F protein. Vaccines (Basel). 2019;7(1):21.
   Web of Science ®Google Scholar
• Quan F, Kim Y, Lee S, et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis. 2011;204(7):987–995.
   PubMed Web of Science ®Google Scholar
• Walpita P, Johns LM, Tandon R, et al. Mammalian cell-derived respiratory syncytial virus-like particles protect the lower as well as the upper respiratory tract. PLoS One. 2015;10(7):e0130755.
   PubMed Web of Science ®Google Scholar
• Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med. 1998;188(10):1967–1972.
   PubMed Web of Science ®Google Scholar
• Sparer TE, Matthews S, Hussell T, et al. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med. 1998;187(11):1921–1926.
   PubMed Web of Science ®Google Scholar
• Kim A, Lee D, Lee S, et al. Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein. PLoS One. 2018;13(1):e0191277.
   PubMed Web of Science ®Google Scholar
• Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012;7(11):e50852.
   PubMed Web of Science ®Google Scholar
• Gilbert BE, Patel N, Lu H, et al. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018;36(52):8069–8078.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434.
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee YT, Hwang HS, et al. Virus-like particle vaccine containing the f protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector T cells. J Virol. 2015;89(22):11692–11705.
   PubMed Web of Science ®Google Scholar
• Cimica V, Boigard H, Bhatia B, et al. Novel respiratory syncytial virus-like particle vaccine composed of the postfusion and prefusion conformations of the F glycoprotein. Clin Vaccine Immunol. 2016;23(6):451–459.
   PubMed Web of Science ®Google Scholar
• Lee S, Quan F, Kwon Y, et al. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antiviral Res. 2014;111:129–135.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Kwon Y, Lee JS, et al. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antiviral Res. 2014;110:115–123.
   PubMed Web of Science ®Google Scholar
• Ko E, Kwon Y, Lee JS, et al. Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells. Nanomedicine. 2015;11(1):99–108.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Lee Y, Kim K, et al. Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus. Virology. 2017;511:142–151.
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee Y, Ko E, et al. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles. Hum Vaccin Immunother. 2017;13(11):2594–2605.
   PubMed Web of Science ®Google Scholar
• Cullen LM, Schmidt MR, Morrison TG. Effect of previous respiratory syncytial virus infection on murine immune responses to F and G protein containing virus-like particles. J Virol. 2019;93(9):e00087–19.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Kim K, Lee Y, et al. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats. Hum Vaccin Immunother. 2017;13(5):1031–1039.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Lee Y, Kim K, et al. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease. Virology. 2016;494:215–224.
   PubMed Web of Science ®Google Scholar
• Raghunandan R, Lu H, Zhou B, et al. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine. 2014;32(48):6485–6492.
   PubMed Web of Science ®Google Scholar
• Blanco JC, Pletneva LM, McGinnes-Cullen L, et al. Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model. Nat Commun. 2018;9(1):1904.
   PubMedGoogle Scholar
• Leyrat C, Paesen GC, Charleston J, et al. Structural insights into the human metapneumovirus glycoprotein ectodomain. J Virol. 2014;88(19):11611–11616.
   PubMed Web of Science ®Google Scholar
• Cseke G, Wright DW, Tollefson SJ, et al. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol. 2007;81(2):698–707.
   PubMed Web of Science ®Google Scholar
• Loo LH, Jumat MR, Fu Y, et al. Evidence for the interaction of the human metapneumovirus G and F proteins during virus-like particle formation. Virol J. 2013;10(1):294.
   PubMedGoogle Scholar
• Wen SC, Schuster JE, Gilchuk P, et al. Lung CD8+ T cell impairment occurs during human metapneumovirus infection despite virus-like particle induction of functional CD8+ T cells. J Virol. 2015;89(17):8713–8726.
   PubMed Web of Science ®Google Scholar
• López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. 2011;29(44):7826–7834.
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol. 2011;85(21):10945–10954.
   PubMed Web of Science ®Google Scholar
• D’Aoust M, Couture MM, Charland N, et al. The production of hemagglutinin‐based virus‐like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010;8(5):607–619.
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trépanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010;5(12):e15559.
   PubMed Web of Science ®Google Scholar
• Pillet S, Couillard J, Trépanier S, et al. Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—two randomized Phase II clinical trials in 18 to 49 and≥ 50 years old adults. PLoS One. 2019;14(6):e0216533.
   PubMed Web of Science ®Google Scholar
• Low JG, Lee LS, Ooi EE, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine. 2014;32(39):5041–5048.
   PubMed Web of Science ®Google Scholar
• Broadbent L, Groves H, Shields MD, et al. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses. 2015;9(4):169–178.
   PubMed Web of Science ®Google Scholar
• Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295–311.
   PubMed Web of Science ®Google Scholar
• Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis. 2015;213(3):411–422.
   PubMed Web of Science ®Google Scholar
• Patel N, Massare MJ, Tian J, et al. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: structure, antigenic profile, immunogenicity, and protection. Vaccine. 2019;37:6112–6124.
   Web of Science ®Google Scholar
• Deng L, Mohan T, Chang TZ, et al. Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat Commun. 2018;9(1):359.
   PubMedGoogle Scholar
• McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–598.
   PubMed Web of Science ®Google Scholar
• Fries L, Shinde V, Stoddard JJ, et al. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. Immun Ageing. 2017;14(1):8.
   PubMedGoogle Scholar